Statistical Models for Quality of Life Measures

  • Yuko Y. Palesch
  • Alan J. Gross


Quality of life (QOL) measures are becoming an integral part of the analysis of clinical trials data to determine the efficacy of interventions. A brief overview of the QOL measures and their corresponding methods of analysis is presented. Then, we propose a statistical model for a discrete QOL measure based on a first order homogeneous Markov process. Heuristically, the model incorporates covariates and allows for nonignorable censoring. Using the model, the efficacy of an intervention can be evaluated by comparing among the treatment groups the expected length of stay in the “good” QOL state in conjunction with the analysis of survival time.


Markov Chain Model Global Index Sickness Impact Profile Accelerate Failure Time Model Quality Adjusted Survival 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bergner M, Bobbitt RA, Carter WB Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Medical Care 19: 787–805, 1981.CrossRefGoogle Scholar
  2. Breslow NE, Day NE. Statistical Methods in Cancer Research, Vol 1. IARC Publications No. 32, IARC, Lyon, France, 1980.Google Scholar
  3. Chambers LN, MacDonald LA, Tugwell P, Buchanan WW, Kraag G. The McMaster Health Index questionnaire as a measure of the quality of life for patients with rheumatic disease. J Rheumatol 90: 780–784, 1982.Google Scholar
  4. Cole BF, Gelber RD, Goldhirsch A. Cox regression models for quality adjusted survival analysis. Statistics in Medicine 12: 975–987, 1993.CrossRefGoogle Scholar
  5. Fix E, Nevman J. A simple stochastic model of recovery, relapse, death and loss of patients. Human Biology 28: 205–241, 1951.Google Scholar
  6. Gelber RD, Gelman RS, Goldhirsch A. A quality of life oriented endpoint for comparing therapies. Biometrics 45: 781–795, 1989.zbMATHCrossRefGoogle Scholar
  7. Glasziou PP, Simes RJ, Gelber RS. Quality adjusted survival analysis. Statistics in Medicine 9: 1259 1276, 1990.Google Scholar
  8. Hadjinicola G, Goldstein L. Markov chain modelling of bioassay toxicity procedures. Statistics in Medicine 12: 661–674, 1993.CrossRefGoogle Scholar
  9. Hillis A, Maguire M, Hawkins BS, Newhouse MM. The Markov process as a general method for nonparametric analysis of right-censored medical data. J Chron Dis 39: 595–604, 1986.CrossRefGoogle Scholar
  10. Hunt SM, McKenna SP, Williams J. Reliability of a population survey tool for measuring perceived health problems: A study of patients with coxarthrosis. J Epidemiol Community Health 35: 297–300, 1981.CrossRefGoogle Scholar
  11. Jaeschke R, Singer J, Guyatt, GH. Measurement of Health Status: Ascertaining the minimally clinically important difference. Controlled Clinical Trials 10: 407–415, 1989.CrossRefGoogle Scholar
  12. Kalbfleisch J, Prentice R.L. The Statistical Analysis of Failure Time Data, Chapter 6. Wiley, New York, 1980.Google Scholar
  13. Kamovsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of nitrogen mustards in the palliative treatment of carcinoma Cancer 20: 634–656. 1948Google Scholar
  14. Kay R. A Markov Model for Analysing cancer markers and disease states in survival studies. Biometrics 42: 855–865, 1986.zbMATHCrossRefGoogle Scholar
  15. Klein JP, Klotz JI, Grever MR. A biological marker model for predicting disease transitions. Biometrics 40: 927–936, 1984.CrossRefGoogle Scholar
  16. Myers LE, Paulson DF, Berry WR et al. A time-dependent statistical model which relates current clinical status to prognosis: Application to advanced prostatic cancer. JChron Dis 33: 491–499, 1980.CrossRefGoogle Scholar
  17. Olschewski M, Schumacher M. Statistical analysis of quality of life data in cancer clinical trials. Statistics in Medicine 9: 749–763, 1990.CrossRefGoogle Scholar
  18. Pepe MS, Longton G, Thornquist M. A qualifier Q for the survival function to describe the prevalence of a transient cndition. Statistics in.Medicine 10: 413–421, 1991.CrossRefGoogle Scholar
  19. Sackett DL, Chambers LW, MacPherson AS, Goldsmith CH, McAuley. RG. The development and application of indices of health: general methods and a summary of results. Am J Public Health 67: 423–428, 1977.CrossRefGoogle Scholar
  20. Schumacher M, Olschewski M, Schulgen G. Assessment of quality of life in clinical trials. Statistics in Medicine 10: 1915–1930, 1991.CrossRefGoogle Scholar
  21. Silverstein MD, Albert DA, Hadler NM, Ropes MW. Prognosis in SLE: comparison of Markov model to life table analysis. J Clin Epidemiol 41: 623–633, 1988.CrossRefGoogle Scholar
  22. Wei LJ. The Accelerated-Failure Time Model: A useful alternative to the cox regression model in survival analysis. Statistics in Medicine 11:1871–1879, 1992.Google Scholar
  23. Zwinderman A. The measurement of change of quality of life in clinical trials. Statistics in Medicine 9: 931–942, 1990.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1996

Authors and Affiliations

  • Yuko Y. Palesch
    • 1
  • Alan J. Gross
    • 1
  1. 1.Medical University of South CarolinaUSA

Personalised recommendations